Advertisement

Gender Differences in Drug Therapy

  • Anthony G FenechEmail author
  • Vanessa Petroni Magri
Living reference work entry

Abstract

Therapeutics has steadily evolved over the last two decades, from a broad system designed to target multiple patients with one management approach to a personalized model that focusses on the characteristics of each individual patient and tailors treatment accordingly. In order to achieve the maximum benefit and minimum risk, personalized medicine needs to address multiple individual parameters including pathology, physiology, genetics, comorbidity, sex and gender. While considerable personalized pharmacotherapeutic advances have been made in all fields, sex and gender have somewhat lagged behind. This has possibly been the result of a long-standing premise that females of childbearing age should be generally omitted from clinical trials. This is now changing. For several years, drug regulatory agencies have been advocating the inclusion of both sexes in preclinical and clinical trial design, ensuring adequate statistical power to discriminate sex-gender differences. This has led to a gradual but steady increase in published data, which highlights sexually dimorphic differences in the pharmacokinetics, pharmacodynamics, and pharmacogenetics of several drugs. Male and female drug metabolism patterns, gene expression profiles, drug interaction pathways, and adverse drug reaction reporting have all contributed to a corpus of knowledge that needs to be constantly expanded and solidified. Furthermore, this information needs to be understood within the context of gender-bias in adherence to therapy and adverse effect reporting. Adherence to medication is a complex matter based on multiple factors including socioeconomic, health system, and patient-specific factors.

Further sex-gender research is required to consolidate and expand current data, within bench-to-bedside translational application frameworks. This needs to be incorporated into all commercial drug development stages. The inclusion of sex-gender differences in independent research needs to be incentivized through peer-review guidelines, grant application priorities and institutional review boards. This drives prospective study design towards research models capable of generating information that contributes towards the inclusion of sex-gender differences in personalized medicine treatment algorithms.

References and Further Reading

  1. Austin KL, Mather LE, Philpot CR, McDonald PJ (1980) Intersubject and dose-related variability after intravenous administration of erythromycin. Br J Clin Pharmacol 10(3):273–279.  https://doi.org/10.1111/j.1365-2125.1980.tb01755.xCrossRefPubMedPubMedCentralGoogle Scholar
  2. Bebawy M, Chetty M (2009) Gender differences in p-glycoprotein expression and function: effects on drug disposition and outcome. Curr Drug Metab 10(4):322–328CrossRefGoogle Scholar
  3. Becker JB, McClellan ML, Reed BG (2017) Sex differences, gender and addiction. J Neurosci Res 95(1–2):136–147.  https://doi.org/10.1002/jnr.23963CrossRefPubMedPubMedCentralGoogle Scholar
  4. Berg UB (2006) Differences in decline in GFR with age between males and females. Reference data on clearances of inulin and PAH in potential kidney donors. Nephrol Dial Transplant Off Publ Eur Dial Transplant Assoc Eur Renal Assoc 21(9):2577–2582.  https://doi.org/10.1093/ndt/gfl227CrossRefGoogle Scholar
  5. Billimek J, Malik S, Sorkin DH, Schmalbach P, Ngo-Metzger Q, Greenfield S, Kaplan SH (2015) Understanding disparities in lipid management among patients with type 2 diabetes: gender differences in medication nonadherence after treatment intensification. Women’s Health Issues Off Publ Jacobs Inst Women’s Health 25(1):6–12.  https://doi.org/10.1016/j.whi.2014.09.004CrossRefGoogle Scholar
  6. Cabaleiro T, Roman M, Ochoa D, Talegon M, Prieto-Perez R, Wojnicz A, Lopez-Rodriguez R, Novalbos J, Abad-Santos F (2013) Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. Drug Metab Dispos 41(1):224–229.  https://doi.org/10.1124/dmd.112.046292CrossRefPubMedGoogle Scholar
  7. Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM (2012) Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the justification for the use of statins in prevention: an intervention trial evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet 5(2):257–264.  https://doi.org/10.1161/CIRCGENETICS.111.961144CrossRefPubMedGoogle Scholar
  8. Coskun T, Sevinc A, Tevetoglu I, Alican I, Kurtel H, Yegen BC (1995) Delayed gastric emptying in conscious male rats following chronic estrogen and progesterone treatment. Research in experimental medicine Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie 195(1):49–54CrossRefGoogle Scholar
  9. Costa E, Giardini A, Savin M, Menditto E, Lehane E, Laosa O, Pecorelli S, Monaco A, Marengoni A (2015) Interventional tools to improve medication adherence: review of literature. Patient Prefer Adherence 9:1303–1314.  https://doi.org/10.2147/PPA.S87551CrossRefPubMedPubMedCentralGoogle Scholar
  10. Damien S, Patural H, Trombert-Paviot B, Beyens MN (2016) Adverse drug reactions in children: 10 years of pharmacovigilance. Archives de pediatrie: organe officiel de la Societe francaise de pediatrie 23(5):468–476.  https://doi.org/10.1016/j.arcped.2016.01.015CrossRefGoogle Scholar
  11. Dauchy S, Dolbeault S, Reich M (2013) Depression in cancer patients. EJC Suppl EJC Off J EORTC European Organization for Research and Treatment of Cancer [et al] 11(2):205–215.  https://doi.org/10.1016/j.ejcsup.2013.07.006CrossRefGoogle Scholar
  12. d'Emden MC, Jenkins AJ, Li L, Zannino D, Mann KP, Best JD, Stuckey BG, Park K, Saltevo J, Keech AC, Investigators FS (2014) Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate intervention and event lowering in diabetes (FIELD) study. Diabetologia 57(11):2296–2303.  https://doi.org/10.1007/s00125-014-3344-3CrossRefPubMedGoogle Scholar
  13. Enck P, Klosterhalfen S (2019) Does sex/gender play a role in placebo and nocebo effects? Conflicting evidence from clinical trials and experimental studies. Front Neurosci 13:160.  https://doi.org/10.3389/fnins.2019.00160CrossRefPubMedPubMedCentralGoogle Scholar
  14. Fadiran EO, Zhang L (2015) Effects of sex differences in the pharmacokinetics of drugs and their impact on the safety of medicines in women. In: Harrison-Woolrych M (ed) Medicines for women. Springer International Publishing, Cham, pp 41–68.  https://doi.org/10.1007/978-3-319-12406-3_2CrossRefGoogle Scholar
  15. Fan X, Wang Y, Sun K, Zhang W, Yang X, Wang S, Zhen Y, Wang J, Li W, Han Y, Liu T, Wang X, Chen J, Wu H, Hui R, Study Group for Pharmacogenomic Based Antihypertensive Drugs Selection E, Side Effects iRAC (2007) Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of captopril in women. Clin Pharmacol Ther 82(2):187–196.  https://doi.org/10.1038/sj.clpt.6100214CrossRefPubMedGoogle Scholar
  16. Feldman M, Richardson CT, Walsh JH (1983) Sex-related differences in gastrin release and parietal cell sensitivity to gastrin in healthy human beings. J Clin Invest 71(3):715–720.  https://doi.org/10.1172/jci110818CrossRefPubMedPubMedCentralGoogle Scholar
  17. Fischer M, Baessler A, Schunkert H (2002) Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res 53(3):672–677CrossRefGoogle Scholar
  18. Food US, Drug A (1993) Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs; notice. Fed Regist 58(139):39406–39416Google Scholar
  19. Franconi F, Carru C, Malorni W, Vella S, Mercuro G (2011) The effect of sex/gender on cardiovascular pharmacology. Curr Pharm Des 17(11):1095–1107CrossRefGoogle Scholar
  20. Fujita A, Hayamizu K, Yoshihara T, Zaitsu M, Shiraishi F, Arima H, Matsuo K, Shiokawa K, Setoguchi H, Sasaguri T (2018) Effect of sex and polymorphisms of CYP2B6 and UGT1A9 on the difference between the target-controlled infusion predicted and measured plasma propofol concentration. JA Clin Rep 4(1):59.  https://doi.org/10.1186/s40981-018-0196-8CrossRefGoogle Scholar
  21. Gabler NB, French B, Strom BL, Liu Z, Palevsky HI, Taichman DB, Kawut SM, Halpern SD (2012) Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest 141(1):20–26.  https://doi.org/10.1378/chest.11-0404CrossRefPubMedPubMedCentralGoogle Scholar
  22. Gabriele L, Buoncervello M, Ascione B, Bellenghi M, Matarrese P, Care A (2016) The gender perspective in cancer research and therapy: novel insights and on-going hypotheses. Annali dell’Istituto superiore di sanita 52(2):213–222.  https://doi.org/10.4415/ANN_16_02_13CrossRefPubMedGoogle Scholar
  23. Gaignebet L, Kararigas G (2017) En route to precision medicine through the integration of biological sex into pharmacogenomics. Clin Sci 131(4):329–342.  https://doi.org/10.1042/CS20160379CrossRefPubMedGoogle Scholar
  24. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362 (17):1563–1574.  https://doi.org/10.1056/NEJMoa1001282
  25. Gonzalez D, Conrado DJ, Theuretzbacher U, Derendorf H (2011) The effect of critical illness on drug distribution. Curr Pharm Biotechnol 12(12):2030–2036CrossRefGoogle Scholar
  26. Grilo A, Saez-Rosas MP, Santos-Morano J, Sanchez E, Moreno-Rey C, Real LM, Ramirez-Lorca R, Saez ME (2011) Identification of genetic factors associated with susceptibility to angiotensin-converting enzyme inhibitors-induced cough. Pharmacogenet Genomics 21(1):10–17.  https://doi.org/10.1097/FPC.0b013e328341041cCrossRefPubMedGoogle Scholar
  27. Group SC, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R (2008) SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med 359(8):789–799.  https://doi.org/10.1056/NEJMoa0801936CrossRefGoogle Scholar
  28. Harmark L, Lie-Kwie M, Berm L, de Gier H, van Grootheest K (2013) Patients' motives for participating in active post-marketing surveillance. Pharmacoepidemiol Drug Saf 22(1):70–76.  https://doi.org/10.1002/pds.3327CrossRefPubMedGoogle Scholar
  29. Ishigami M, Kawabata K, Takasaki W, Ikeda T, Komai T, Ito K, Sugiyama Y (2001) Drug interaction between simvastatin and itraconazole in male and female rats. Drug Metab Dispos 29(7):1068–1072PubMedGoogle Scholar
  30. Jankovic SM, Pejcic AV, Milosavljevic MN, Opancina VD, Pesic NV, Nedeljkovic TT, Babic GM (2018) Risk factors for potential drug-drug interactions in intensive care unit patients. J Crit Care 43:1–6.  https://doi.org/10.1016/j.jcrc.2017.08.021CrossRefPubMedGoogle Scholar
  31. Jessurun N, van Marum R, Hermens W, van Puijenbroek E (2016) Advanced age and female sex as risk factors for high anion gap metabolic acidosis after a Drug interaction between paracetamol and Flucloxacillin: a case series. J Am Geriatr Soc 64(10):e90–e93.  https://doi.org/10.1111/jgs.14332CrossRefPubMedGoogle Scholar
  32. Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V (2005) Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J 26(16):1585–1595.  https://doi.org/10.1093/eurheartj/ehi397CrossRefPubMedGoogle Scholar
  33. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ (2004) Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am J Cardiol 93(8):1046–1050.  https://doi.org/10.1016/j.amjcard.2004.01.014CrossRefPubMedGoogle Scholar
  34. Kajinami K, Brousseau ME, Lamon-Fava S, Ordovas JM, Schaefer EJ (2005) Gender-specific effects of estrogen receptor alpha gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: interaction with apolipoprotein AI gene polymorphism. Atherosclerosis 178(2):331–338.  https://doi.org/10.1016/j.atherosclerosis.2004.08.034CrossRefPubMedGoogle Scholar
  35. Karagiannis TC (2014) The timeless influence of Hippocratic ideals on diet, salicytates and personalized medicine. Hell J Nucl Med 17(1):2–6.  https://doi.org/10.1967/s0024499100110CrossRefPubMedGoogle Scholar
  36. Kautzky-Willer A, Harreiter J (2017) Sex and gender differences in therapy of type 2 diabetes. Diabetes Res Clin Pract 131:230–241.  https://doi.org/10.1016/j.diabres.2017.07.012CrossRefPubMedGoogle Scholar
  37. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70(2):189–199.  https://doi.org/10.1067/mcp.2001.117412CrossRefPubMedGoogle Scholar
  38. Kim AM, Tingen CM, Woodruff TK (2010) Sex bias in trials and treatment must end. Nature 465(7299):688–689.  https://doi.org/10.1038/465688aCrossRefPubMedGoogle Scholar
  39. Kishino S, Nomura A, Itoh S, Nakagawa T, Takekuma Y, Sugawara M, Furukawa H, Todo S, Miyazaki K (2002) Age- and gender-related differences in carbohydrate concentrations of alpha1-acid glycoprotein variants and the effects of glycoforms on their drug-binding capacities. Eur J Clin Pharmacol 58(9):621–628.  https://doi.org/10.1007/s00228-002-0530-xCrossRefPubMedGoogle Scholar
  40. Kloner RA, Sowers JR, DiBona GF, Gaffney M, Wein M (1996) Sex- and age-related antihypertensive effects of amlodipine. The amlodipine cardiovascular community trial study group. Am J Cardiol 77(9):713–722CrossRefGoogle Scholar
  41. Kneale BJ, Chowienczyk PJ, Brett SE, Coltart DJ, Ritter JM (2000) Gender differences in sensitivity to adrenergic agonists of forearm resistance vasculature. J Am Coll Cardiol 36(4):1233–1238CrossRefGoogle Scholar
  42. Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI, Gelenberg AJ, Davis SM, Harrison WM, Keller MB (2000) Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 157(9):1445–1452.  https://doi.org/10.1176/appi.ajp.157.9.1445CrossRefPubMedGoogle Scholar
  43. Krecic-Shepard ME, Barnas CR, Slimko J, Schwartz JB (2000) Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. Clin Pharmacol Ther 68(3):286–292.  https://doi.org/10.1067/mcp.2000.109356CrossRefPubMedGoogle Scholar
  44. Lehmann MH, Hardy S, Archibald D, quart B, MacNeil DJ (1996) Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation 94(10):2535–2541CrossRefGoogle Scholar
  45. Li Q, Zhou T, Wu F, Li N, Wang R, Zhao Q, Ma YM, Zhang JQ, Ma BL (2018) Subcellular drug distribution: mechanisms and roles in drug efficacy, toxicity, resistance, and targeted delivery. Drug Metab Rev 50(4):430–447.  https://doi.org/10.1080/03602532.2018.1512614CrossRefPubMedGoogle Scholar
  46. Linden W, Vodermaier A, Mackenzie R, Greig D (2012) Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. J Affect Disord 141(2–3):343–351.  https://doi.org/10.1016/j.jad.2012.03.025CrossRefPubMedGoogle Scholar
  47. Lucotte EA, Laurent R, Heyer E, Segurel L, Toupance B (2016) Detection of allelic frequency differences between the sexes in humans: a signature of sexually antagonistic selection. Genome Biol Evol 8(5):1489–1500.  https://doi.org/10.1093/gbe/evw090CrossRefPubMedPubMedCentralGoogle Scholar
  48. MacGowan SH, Wilcock GK, Scott M (1998) Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer’s disease. Int J Geriatr Psychiatry 13(9):625–630CrossRefGoogle Scholar
  49. Manni A, Direnzo V, Iaffaldano A, Di Lecce V, Tortorella C, Zoccolella S, Iaffaldano P, Trojano M, Paolicelli D (2017) Gender differences in safety issues during Fingolimod therapy: evidence from a real-life relapsing multiple sclerosis cohort. Brain Behav 7(10):e00804.  https://doi.org/10.1002/brb3.804CrossRefPubMedPubMedCentralGoogle Scholar
  50. Manteuffel M, Williams S, Chen W, Verbrugge RR, Pittman DG, Steinkellner A (2014) Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines. J Women’s Health 23(2):112–119.  https://doi.org/10.1089/jwh.2012.3972CrossRefGoogle Scholar
  51. Markle JG, Fish EN (2014) SeXX matters in immunity. Trends Immunol 35(3):97–104.  https://doi.org/10.1016/j.it.2013.10.006CrossRefPubMedGoogle Scholar
  52. McGill JB, Vlajnic A, Knutsen PG, Recklein C, Rimler M, Fisher SJ (2013) Effect of gender on treatment outcomes in type 2 diabetes mellitus. Diabetes Res Clin Pract 102(3):167–174.  https://doi.org/10.1016/j.diabres.2013.10.001CrossRefPubMedGoogle Scholar
  53. McGregor AJ, Hasnain M, Sandberg K, Morrison MF, Berlin M, Trott J (2016) How to study the impact of sex and gender in medical research: a review of resources. Biol Sex Differ 7(Suppl 1):46.  https://doi.org/10.1186/s13293-016-0099-1CrossRefPubMedPubMedCentralGoogle Scholar
  54. Mega JL, Morrow DA, Brown A, Cannon CP, Sabatine MS (2009) Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol 29(9):1310–1315.  https://doi.org/10.1161/ATVBAHA.109.188474CrossRefPubMedGoogle Scholar
  55. Mills PJ, Ziegler MG, Nelesen RA, Kennedy BP (1996) The effects of the menstrual cycle, race, and gender on adrenergic receptors and agonists. Clin Pharmacol Ther 60(1):99–104.  https://doi.org/10.1016/S0009-9236(96)90172-1CrossRefPubMedGoogle Scholar
  56. Montastruc JL, Lapeyre-Mestre M, Bagheri H, Fooladi A (2002) Gender differences in adverse drug reactions: analysis of spontaneous reports to a regional pharmacovigilance Centre in France. Fundam Clin Pharmacol 16(5):343–346CrossRefGoogle Scholar
  57. Morissette P, Albert C, Busque S, St-Louis G, Vinet B (2001) In vivo higher glucuronidation of mycophenolic acid in male than in female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil. Ther Drug Monit 23(5):520–525CrossRefGoogle Scholar
  58. Mukonzo JK, Roshammar D, Waako P, Andersson M, Fukasawa T, Milani L, Svensson JO, Ogwal-Okeng J, Gustafsson LL, Aklillu E (2009) A novel polymorphism in ABCB1 gene, CYP2B6∗6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol 68(5):690–699.  https://doi.org/10.1111/j.1365-2125.2009.03516.xCrossRefPubMedPubMedCentralGoogle Scholar
  59. Nakagawa K, Kajiwara A (2015) Female sex as a risk factor for adverse drug reactions. Nihon Rinsho 73(4):581–585PubMedGoogle Scholar
  60. Nicolas JM, Espie P, Molimard M (2009) Gender and interindividual variability in pharmacokinetics. Drug Metab Rev 41(3):408–421.  https://doi.org/10.1080/10837450902891485CrossRefPubMedGoogle Scholar
  61. Oertelt-Prigione S, Regitz-Zagrosek V (2009) Gender aspects in cardiovascular pharmacology. J Cardiovasc Transl Res 2(3):258–266.  https://doi.org/10.1007/s12265-009-9114-9CrossRefPubMedGoogle Scholar
  62. Pinquart M, Duberstein PR (2010) Depression and cancer mortality: a meta-analysis. Psychol Med 40(11):1797–1810.  https://doi.org/10.1017/S0033291709992285CrossRefPubMedPubMedCentralGoogle Scholar
  63. Puri R, Nissen SE, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Libby P, Raichlen JS, Uno K, Kataoka Y, Nicholls SJ (2014) Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN. J Am Coll Cardiol Img 7(10):1013–1022.  https://doi.org/10.1016/j.jcmg.2014.04.019CrossRefGoogle Scholar
  64. Rathore SS, Wang Y, Krumholz HM (2002) Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347(18):1403–1411.  https://doi.org/10.1056/NEJMoa021266CrossRefPubMedGoogle Scholar
  65. Ratnu VS, Emami MR, Bredy TW (2017) Genetic and epigenetic factors underlying sex differences in the regulation of gene expression in the brain. J Neurosci Res 95(1–2):301–310.  https://doi.org/10.1002/jnr.23886CrossRefPubMedPubMedCentralGoogle Scholar
  66. Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA (2011) Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff 30(1):91–99.  https://doi.org/10.1377/hlthaff.2009.1087CrossRefGoogle Scholar
  67. Rosano GM, Lewis B, Agewall S, Wassmann S, Vitale C, Schmidt H, Drexel H, Patak A, Torp-Pedersen C, Kjeldsen KP, Tamargo J (2015) Gender differences in the effect of cardiovascular drugs: a position document of the working group on pharmacology and Drug therapy of the ESC. Eur Heart J 36(40):2677–2680.  https://doi.org/10.1093/eurheartj/ehv161CrossRefPubMedGoogle Scholar
  68. Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ (2004) Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 24(1):70–78.  https://doi.org/10.1097/01.jcp.0000106221.36344.4dCrossRefPubMedGoogle Scholar
  69. Ruan YF, Liu N, Zhou Q, Li Y, Wang L (2004) Experimental study on the mechanism of sex difference in the risk of torsade de pointes. Chin Med J 117(4):538–541PubMedGoogle Scholar
  70. Schmetzer O, Florcken A (2012) Sex differences in the drug therapy for oncologic diseases. Handb Exp Pharmacol 214:411–442.  https://doi.org/10.1007/978-3-642-30726-3_19CrossRefGoogle Scholar
  71. Schwartz JB (2003) The influence of sex on pharmacokinetics. Clin Pharmacokinet 42(2):107–121.  https://doi.org/10.2165/00003088-200342020-00001CrossRefPubMedGoogle Scholar
  72. Schwartz JB (2007) The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther 82(1):87–96.  https://doi.org/10.1038/sj.clpt.6100226CrossRefPubMedGoogle Scholar
  73. Smiderle L, Lima LO, Hutz MH, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, Almeida S, Fiegenbaum M (2014) Evaluation of sexual dimorphism in the efficacy and safety of simvastatin/atorvastatin therapy in a southern Brazilian cohort. Arq Bras Cardiol 103(1):33–40PubMedPubMedCentralGoogle Scholar
  74. Smiderle L, Fiegenbaum M, Hutz MH, Van Der Sand CR, Van Der Sand LC, Ferreira ME, Pires RC, Almeida S (2016) ESR1 polymorphisms and statin therapy: a sex-specific approach. Pharmacogenomics J 16(6):507–513.  https://doi.org/10.1038/tpj.2015.60CrossRefPubMedGoogle Scholar
  75. Smith HR (2015) Depression in cancer patients: pathogenesis, implications and treatment (review). Oncol Lett 9(4):1509–1514.  https://doi.org/10.3892/ol.2015.2944CrossRefPubMedPubMedCentralGoogle Scholar
  76. Soldin OP, Mattison DR (2009) Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 48(3):143–157.  https://doi.org/10.2165/00003088-200948030-00001CrossRefPubMedPubMedCentralGoogle Scholar
  77. Soldin OP, Chung SH, Mattison DR (2011) Sex differences in drug disposition. J Biomed Biotechnol 2011:187103.  https://doi.org/10.1155/2011/187103CrossRefPubMedPubMedCentralGoogle Scholar
  78. Spranger M, Aspey BS, Harrison MJ (1989) Sex difference in antithrombotic effect of aspirin. Stroke 20(1):34–37CrossRefGoogle Scholar
  79. Spratt KA (1997) Sex- and age-related antihypertensive effects of amlodipine. Am J Cardiol 79(6):843–844CrossRefGoogle Scholar
  80. Stolarz AJ, Rusch NJ (2015) Gender differences in cardiovascular drugs. Cardiovasc Drugs Ther 29(4):403–410.  https://doi.org/10.1007/s10557-015-6611-8CrossRefPubMedGoogle Scholar
  81. Stramba-Badiale M, Locati EH, Martinelli A, Courville J, Schwartz PJ (1997) Gender and the relationship between ventricular repolarization and cardiac cycle length during 24-h Holter recordings. Eur Heart J 18(6):1000–1006CrossRefGoogle Scholar
  82. Sykiotis GP, Kalliolias GD, Papavassiliou AG (2005) Pharmacogenetic principles in the Hippocratic writings. J Clin Pharmacol 45(11):1218–1220.  https://doi.org/10.1177/0091270005281091CrossRefPubMedGoogle Scholar
  83. Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM (1992) Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 2(4):148–159CrossRefGoogle Scholar
  84. Theusch E, Kim K, Stevens K, Smith JD, Chen YI, Rotter JI, Nickerson DA, Medina MW (2017) Statin-induced expression change of INSIG1 in lymphoblastoid cell lines correlates with plasma triglyceride statin response in a sex-specific manner. Pharmacogenomics J 17(3):222–229.  https://doi.org/10.1038/tpj.2016.12CrossRefPubMedGoogle Scholar
  85. Trenaman SC, Rideout M, Andrew MK (2019) Sex and gender differences in polypharmacy in persons with dementia: a scoping review. SAGE Open Med 7:2050312119845715.  https://doi.org/10.1177/2050312119845715CrossRefPubMedPubMedCentralGoogle Scholar
  86. Unschuld PG, Ising M, Roeske D, Erhardt A, Specht M, Kloiber S, Uhr M, Muller-Myhsok B, Holsboer F, Binder EB (2010) Gender-specific association of galanin polymorphisms with HPA-axis dysregulation, symptom severity, and antidepressant treatment response. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 35(7):1583–1592.  https://doi.org/10.1038/npp.2010.30CrossRefGoogle Scholar
  87. Vambheim SM, Flaten MA (2017) A systematic review of sex differences in the placebo and the nocebo effect. J Pain Res 10:1831–1839.  https://doi.org/10.2147/JPR.S134745CrossRefPubMedPubMedCentralGoogle Scholar
  88. Venturini CD, Engroff P, Ely LS, Zago LF, Schroeter G, Gomes I, De Carli GA, Morrone FB (2011) Gender differences, polypharmacy, and potential pharmacological interactions in the elderly. Clinics 66(11):1867–1872.  https://doi.org/10.1590/s1807-59322011001100004CrossRefPubMedPubMedCentralGoogle Scholar
  89. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W (2011) Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 11(4):274–286.  https://doi.org/10.1038/tpj.2010.28CrossRefPubMedGoogle Scholar
  90. WHO (2003) Adherence to long-term therapies: evidence for actionGoogle Scholar
  91. WHO (2017) Depression and other common mental disorders: global health estimatesGoogle Scholar
  92. Woodard-Grice AV, Lucisano AC, Byrd JB, Stone ER, Simmons WH, Brown NJ (2010) Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics 20(9):532–536.  https://doi.org/10.1097/FPC.0b013e32833d3acbCrossRefPubMedPubMedCentralGoogle Scholar
  93. Wrobel G, Mauguen A, Rosolen A, Reiter A, Williams D, Horibe K, Brugieres L, Le Deley MC, European Inter-Group for Childhood N-HL (2011) Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: report of the ALCL99 randomised trial. Pediatr Blood Cancer 56(7):1071–1077.  https://doi.org/10.1002/pbc.22940CrossRefPubMedGoogle Scholar
  94. Yang X, Zhang B, Molony C, Chudin E, Hao K, Zhu J, Gaedigk A, Suver C, Zhong H, Leeder JS, Guengerich FP, Strom SC, Schuetz E, Rushmore TH, Ulrich RG, Slatter JG, Schadt EE, Kasarskis A, Lum PY (2010) Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res 20(8):1020–1036.  https://doi.org/10.1101/gr.103341.109CrossRefPubMedPubMedCentralGoogle Scholar
  95. Yang L, Li Y, Hong H, Chang CW, Guo LW, Lyn-Cook B, Shi L, Ning B (2012) Sex differences in the expression of Drug-metabolizing and transporter genes in human liver. J Drug Metab Toxicol 3(3):1000119.  https://doi.org/10.4172/2157-7609.1000119CrossRefPubMedPubMedCentralGoogle Scholar
  96. Young EA, Kornstein SG, Marcus SM, Harvey AT, Warden D, Wisniewski SR, Balasubramani GK, Fava M, Trivedi MH, John Rush A (2009) Sex differences in response to citalopram: a STAR∗D report. J Psychiatr Res 43(5):503–511.  https://doi.org/10.1016/j.jpsychires.2008.07.002CrossRefPubMedGoogle Scholar
  97. Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138(1):103–141.  https://doi.org/10.1016/j.pharmthera.2012.12.007CrossRefPubMedGoogle Scholar
  98. Zhang Y, Klein K, Sugathan A, Nassery N, Dombkowski A, Zanger UM, Waxman DJ (2011) Transcriptional profiling of human liver identifies sex-biased genes associated with polygenic dyslipidemia and coronary artery disease. PLoS One 6(8):e23506.  https://doi.org/10.1371/journal.pone.0023506CrossRefPubMedPubMedCentralGoogle Scholar
  99. Zhu B, Liu ZQ, Chen GL, Chen XP, Ou-Yang DS, Wang LS, Huang SL, Tan ZR, Zhou HH (2003) The distribution and gender difference of CYP3A activity in Chinese subjects. Br J Clin Pharmacol 55(3):264–269CrossRefGoogle Scholar
  100. Ziegler SM, Beisel C, Sutter K, Griesbeck M, Hildebrandt H, Hagen SH, Dittmer U, Altfeld M (2017) Human pDCs display sex-specific differences in type I interferon subtypes and interferon alpha/beta receptor expression. Eur J Immunol 47(2):251–256.  https://doi.org/10.1002/eji.201646725CrossRefPubMedGoogle Scholar
  101. Zuo L, Wang T, Lin X, Wang J, Tan Y, Wang X, Yu X, Luo X (2015) Sex difference of autosomal alleles in populations of European and African descent. Genes Genomics 37(12):1007–1016.  https://doi.org/10.1007/s13258-015-0332-zCrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Clinical Pharmacology and TherapeuticsUniversity of MaltaMsidaMalta

Personalised recommendations